Aphelion Drug Patent Portfolio
Aphelion owns 1 orange book drug protected by 6 US patents Given below is the list of Aphelion's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10947197 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL | 09 Jun, 2037 | Active |
| US11851407 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL | 09 Jun, 2037 | Active |
| US8778305 | PSMA-binding agents and uses thereof | 21 Sep, 2030 | Active |
| US12070513 | PSMA-binding agents and uses thereof | 31 Jul, 2029 | Active |
| US9861713 | PSMA-binding agents and uses thereof | 31 Jul, 2029 | Active |
| US8487129 | Heterodimers of glutamic acid | 07 Nov, 2027 | Active |
Aphelion Drug Patents' Oppositions Filed in EPO
Aphelion drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 23, 2021, by Lewis Silkin Llp. This opposition was filed on patent number EP18150494A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19214298A | Jan, 2023 | Telix Innovations S.A. | Granted and Under Opposition |
| EP18150494A | Sep, 2021 | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg | Revoked |
| EP18150494A | Sep, 2021 | POLSERVICE KANCELARIA RZECZNIKOW PATENTOWYCH SP. Z O.O. | Revoked |
| EP18150494A | Sep, 2021 | Lewis Silkin LLP | Revoked |
Aphelion's Family Patents
Aphelion Drug List
Given below is the complete list of Aphelion's drugs and the patents protecting them.
1. Pylarify Truvu
Pylarify Truvu is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10947197 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
09 Jun, 2037
(11 years from now)
| Active |
| US11851407 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
09 Jun, 2037
(11 years from now)
| Active |
| US8778305 | PSMA-binding agents and uses thereof |
21 Sep, 2030
(4 years from now)
| Active |
| US12070513 | PSMA-binding agents and uses thereof |
31 Jul, 2029
(3 years from now)
| Active |
| US9861713 | PSMA-binding agents and uses thereof |
31 Jul, 2029
(3 years from now)
| Active |
| US8487129 | Heterodimers of glutamic acid |
07 Nov, 2027
(1 year, 6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pylarify Truvu's drug page